Le Lézard
Classified in: Health
Subject: NPT

Lennox-Gastaut Syndrome (LGS) Foundation Announces Exciting New Research Funded in Time for the 9th Annual Walk 'n' Wheel for LGS Research


SAN DIEGO, April 16, 2024 /PRNewswire/ -- On April 20, 2024, the Lennox-Gastaut Syndrome (LGS) Foundation will mobilize families, friends, and communities around the world to 'Step Towards the Cures, Together' at their 9th Annual Walk 'n' Wheel for LGS Research. Click here to learn how you can get involved.

Lennox-Gastaut Syndrome (LGS) is a rare, severe, life-threatening epilepsy syndrome that develops in children and leads to lifelong disability. About 50,000 people in the United States and 1 million people worldwide have LGS. There are no cures for LGS. Together, we can change this!

"Watching Nyla endure years of relentless seizures and the numerous other battles that come with living with LGS fuels my determination to fight alongside her for improved treatments, resources, and support. Every step forward in raising awareness brings hope not just to her, but to all those affected by this terrible disease. This journey isn't just about making a difference for Nyla; it's about creating a brighter future for everyone impacted by LGS." - Erika, Mom to Nyla, Living with LGS.

All funds raised at this event go directly to the LGS Foundation's Finding the Cures, Together Research Program. This vital program drives cutting-edge research that leads to new therapies and treatments for those devastated by LGS.

A critical part of this Research Program is funding patient-led research by awarding Cure LGS 365 Research Grants. The LGS Foundation recently funded an exciting new research study conducted by Drs. Juliet Knowles and Zach Grinspan of Stanford University School of Medicine and Weill Cornell School of Medicine. The research project will identify risk factors and predict the progression of LGS in young children.

"Dr. Knowles and Dr. Grinspan's work is critical to our mission of finding cures and without the funds raised from our community and the Walk 'n' Wheel, we wouldn't have been able to advance this important work," says Dr. Tracy Dixon-Salazar, Executive Director of the LGS Foundation and mom to a 30-year-old daughter who has LGS. "This disease evolves over time in young children, and we know very little about who is at risk. This research project will help us understand the risk factors that lead to LGS and may eventually allow us to intervene before LGS develops." 

For more information, visit the LGS Foundation's website.

About the LGS Foundation
The Lennox-Gastaut Syndrome (LGS) Foundation is a nonprofit organization dedicated to improving the lives of individuals impacted by LGS. It educates the public about LGS, supports families living with the condition, and drives research to find the cures.

SOURCE Lennox-Gastaut Syndrome (LGS) Foundation


These press releases may also interest you

at 17:55
City of Hope®, one of the largest cancer research and treatment organizations in the United States, has been awarded $5.4 million from the California Institute for Regenerative Medicine (CIRM) to build and fund a stem cell research laboratory on its...

at 17:25
Talphera, Inc. , ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Board of Directors of Talphera has granted...

at 16:56
A paper published in the June edition of the Journal Diabetes demonstrates that C-peptide, a biomarker that indicates the production of insulin, is a validated surrogate endpoint, or predictor of clinical benefit, for clinical trials of...

at 16:28
?Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the QOL-B Respiratory Domain Instrument? ?QOL-B...

at 16:20
Jarrard Inc., a leading national healthcare strategic communications consultancy, has expanded by 10 percent, adding seven new professionals to address the increasing demand for its healthcare advisory services. The team now includes 81 full-time...

at 16:10
Pulse Biosciences, Inc. ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that the Company's Board of Directors has determined a new record...



News published on and distributed by: